DE69713948D1 - Rasch-freisetzende pH-unabhängige feste Dosisformen enthaltend Cisaprid - Google Patents

Rasch-freisetzende pH-unabhängige feste Dosisformen enthaltend Cisaprid

Info

Publication number
DE69713948D1
DE69713948D1 DE69713948T DE69713948T DE69713948D1 DE 69713948 D1 DE69713948 D1 DE 69713948D1 DE 69713948 T DE69713948 T DE 69713948T DE 69713948 T DE69713948 T DE 69713948T DE 69713948 D1 DE69713948 D1 DE 69713948D1
Authority
DE
Germany
Prior art keywords
dosage forms
solid dosage
forms containing
rapidly releasing
independent solid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69713948T
Other languages
English (en)
Inventor
Paul Marie Victor Gilis
Guido Franciscus Smans
Guido Jozef Maria Gijs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of DE69713948D1 publication Critical patent/DE69713948D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69713948T 1996-04-23 1997-03-11 Rasch-freisetzende pH-unabhängige feste Dosisformen enthaltend Cisaprid Expired - Lifetime DE69713948D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96201078 1996-04-23

Publications (1)

Publication Number Publication Date
DE69713948D1 true DE69713948D1 (de) 2002-08-22

Family

ID=8223900

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69713948T Expired - Lifetime DE69713948D1 (de) 1996-04-23 1997-03-11 Rasch-freisetzende pH-unabhängige feste Dosisformen enthaltend Cisaprid

Country Status (23)

Country Link
US (1) US6030988A (de)
JP (1) JPH10510559A (de)
KR (1) KR100204115B1 (de)
CN (1) CN1216467A (de)
AR (1) AR006790A1 (de)
AT (1) ATE220543T1 (de)
AU (1) AU720582B2 (de)
BG (1) BG102812A (de)
BR (1) BR9708585A (de)
CA (1) CA2201264C (de)
CZ (1) CZ332598A3 (de)
DE (1) DE69713948D1 (de)
EA (1) EA000804B1 (de)
EE (1) EE03552B1 (de)
ID (1) ID16666A (de)
IL (1) IL125979A0 (de)
NO (1) NO984016L (de)
NZ (1) NZ331705A (de)
PL (1) PL328917A1 (de)
SK (1) SK144698A3 (de)
TR (1) TR199802139T2 (de)
WO (1) WO1997039744A1 (de)
ZA (1) ZA973449B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US20030138485A1 (en) * 1998-01-14 2003-07-24 Daiichi Pharmaceutical Co., Ltd. Disintegrant
US20020039597A1 (en) * 1998-04-20 2002-04-04 Koji Ukai Stabilized compositions containing benzimidazole-type compounds
TW407058B (en) * 1998-07-17 2000-10-01 Dev Center Biotechnology Oral cisapride dosage forms with an extended duration
US6353005B1 (en) * 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
ES2288876T3 (es) 1999-10-20 2008-02-01 EISAI R&D MANAGEMENT CO., LTD. Procedimiento para estabilizar compuestos de bencimidazol.
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
SE0100200D0 (sv) * 2001-01-24 2001-01-24 Astrazeneca Ab New film coating
US6407128B1 (en) 2001-12-03 2002-06-18 Elan Pharmaceuticals, Inc. Method for increasing the bioavailability of metaxalone
US7714006B1 (en) 2001-12-03 2010-05-11 King Pharmaceuticals Research & Development, Inc. Methods of modifying the bioavailability of metaxalone
DE10164510A1 (de) * 2001-12-20 2003-07-10 Schering Ag Orale Fludara reinst Formulierung mit schneller Freisetzung des Wirkstoffes
EP1321142A1 (de) * 2001-12-21 2003-06-25 Novartis AG Feste orale Zubereitung mit Tegaserod
HRP20020124A2 (en) * 2002-02-11 2003-10-31 Pliva D D Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping
GB2390541A (en) * 2002-07-12 2004-01-14 Reckitt Benckiser Healthcare Medicinal composition comprising fibre or saccharide bulking agents
WO2004019937A1 (en) * 2002-09-02 2004-03-11 Sun Pharmaceutical Industries Limited Pharmaceutical composition of metaxalone with enhanced oral bioavailability
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
MXPA06000529A (es) * 2003-07-18 2006-08-11 Santarus Inc Formulaciones farmaceuticas utiles para inhibir la secrecion de acido y metodos para elaborarlas y utilizarlas.
EP1648417A4 (de) * 2003-07-18 2010-01-20 Santarus Inc Pharmazeutische formulierung und verfahren zur behandlung von säurebedingten gastrointestinalen erkrankungen
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
US8138204B2 (en) * 2004-01-07 2012-03-20 Aryx Therapeutics, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US8524736B2 (en) 2004-01-07 2013-09-03 Armetheon, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
EP1718303A4 (de) * 2004-02-10 2010-09-01 Santarus Inc Kombination eines protonenpumpenhemmers, puffermittels und einem nichtsteroidalen entzündungshemmenden mittel
CA2561700A1 (en) * 2004-04-16 2005-12-15 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8022053B2 (en) * 2004-11-02 2011-09-20 Bayer Schering Pharma Aktiengesellschaft Oral solid dosage forms containing a low dose of estradiol
EA015155B1 (ru) * 2005-05-26 2011-06-30 Тева Вуменс Хелс, Инк. Дозированные формы для перорального применения, содержащие прогестерон, и способы их изготовления и использования
CN1935264B (zh) * 2005-09-23 2010-05-05 北京德众万全医药科技有限公司 一种用于缓控释片的含有hpmc的新型复合辅料
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
TW200843802A (en) * 2007-02-09 2008-11-16 Drugtech Corp Compositions for improving gastrointestinal nutrient and drug absorption
CN104352465B (zh) * 2014-11-17 2017-04-12 成都新恒创药业有限公司 一种不含二氧化硅的琥珀酸普芦卡必利药物组合物及其制备方法
CN109394711A (zh) * 2018-11-06 2019-03-01 威海贯标信息科技有限公司 一种酒石酸西尼必利片组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962115A (en) * 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
JPH08502032A (ja) * 1992-07-07 1996-03-05 セプラコア インコーポレーテッド 胃食道逆流疾患およびその他の障害を治療するために▲（−）▼シサプリドを使用する方法
EP1170010A3 (de) * 1992-07-07 2004-05-19 Sepracor Inc. Verfahren zur Verwendung von (+) -Cisaprid zur Behandlung der Reflux-Ösophagitisund anderer Erkrankungen
CA2166730A1 (en) * 1993-07-06 1995-01-19 Robert T. Sims H2 antagonist-gastrointestinal motility agent combinations
ES2136157T3 (es) * 1994-03-01 1999-11-16 Gerhard Gergely Producto granular o comprimido que contiene un sistema efervescente y una sustancia farmaceutica activa, asi como un procedimiento para su preparacion.
CH686865A5 (de) * 1994-06-15 1996-07-31 Gergely Gerhard Pharmazeutische Zubereitung mit einem hydrophoben Wirkstoff und einem Brausesystem, sowie Verfahren zur Herstellung der Zubereitung.
ZA959221B (en) * 1994-11-02 1997-04-30 Janssen Pharmaceutica Nv Cisapride extended release

Also Published As

Publication number Publication date
EA199800861A1 (ru) 1999-02-25
NO984016L (no) 1998-12-23
ATE220543T1 (de) 2002-08-15
NZ331705A (en) 1999-11-29
EA000804B1 (ru) 2000-04-24
KR100204115B1 (ko) 1999-06-15
SK144698A3 (en) 1999-05-07
BR9708585A (pt) 1999-08-03
EE9800269A (et) 1999-02-15
EE03552B1 (et) 2001-12-17
AR006790A1 (es) 1999-09-29
WO1997039744A1 (en) 1997-10-30
CZ332598A3 (cs) 1999-01-13
ZA973449B (en) 1998-10-22
CN1216467A (zh) 1999-05-12
PL328917A1 (en) 1999-03-01
US6030988A (en) 2000-02-29
KR970069038A (ko) 1997-11-07
IL125979A0 (en) 1999-04-11
CA2201264A1 (en) 1997-10-23
AU2290497A (en) 1997-11-12
AU720582B2 (en) 2000-06-08
JPH10510559A (ja) 1998-10-13
ID16666A (id) 1997-10-30
BG102812A (en) 1999-05-31
CA2201264C (en) 1999-08-10
TR199802139T2 (xx) 1999-03-22
NO984016D0 (no) 1998-09-01

Similar Documents

Publication Publication Date Title
DE69713948D1 (de) Rasch-freisetzende pH-unabhängige feste Dosisformen enthaltend Cisaprid
ID18427A (id) Pengkabut serbuk
DE59708196D1 (de) Rastschaltwerk
BR9709956A (pt) Formas de dosagem oral sólidas de valsartan
DE59707194D1 (de) Direkttablettierhilfsmittel
FR2745429B1 (fr) Gaine annelee fendue
DE69731046D1 (de) Sicherheitsbehälter
TR199501351A2 (tr) Uzatilmis sürede cisaprid saliverilmesi.
FI962420A0 (fi) Foerstaerkare med laogbrus
NO983090D0 (no) Terapeutiske forbindelser
FI962419A0 (fi) Ringoskillator med hoeg hastighet
EE03511B1 (et) Misolastiini sisaldavad prolongeeritud toimega farmatseutilised preparaadid
FR2753102B3 (fr) Bille intra-orbitaire
DE59706259D1 (de) Palatinalsplitschraube
DE29621807U1 (de) Konfektionierte Teilkronen
DE29716623U1 (de) Zahnprothese
DE29606681U1 (de) Spielwürfel
KR970053579U (ko) 아령
DE29618094U1 (de) Pharmazeutisches Präparat
PT914233E (pt) Dispositivo de dosagem
KR970063651U (ko) 타이머의 현재시간 재설정장치
DE69700366T2 (de) Stabmixer
KR960035325U (ko) 분리형 감지기
DE29605995U1 (de) Stelzen
DE29606865U1 (de) Artikulator